Cardiovascular Effects of Prenatal Methamphetamine Exposure

Status Recruiting

Clinical Trial Summary

Methamphetamine (MA) is one of the commonly used drugs during pregnancy. Cardiovascular effects of MA include elevated blood pressure, acute vasospasm, atherosclerotic disease, structural and electrical remodeling of cardiac tissue leading to arrhythmias and heart failure, and pulmonary hypertension.1 In addition, MA can cause neurotoxicity with harmful effects on neurodevelopment in the children who had prenatal exposure.5-8 Currently neonatal providers do not perform detailed cardiovascular evaluation in newborn period or long term neurodevelopmental assessments as outpatient for the newly born infants with prenatal exposure to MA, and they do not qualify for early intervention. The goal of the investigators is to perform detailed cardiovascular evaluation in neonatal period and estimate baseline prevalences and follow up with developmental and cardiovascular assessment using a questionnaire at 12 months in a cohort of neonates enriched with those who had prenatal exposure to MA.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Methamphetamine Abuse
Newborn Complication &#X7C; Patient &#X7C; Neonatalology

Clinical Trial Details

NCT number	NCT04616625
Study type	Observational
Source	University of California, Davis
Contact	Deepika Sankaran, MD
Phone	3477410372
Email	dsankaran@ucdavis.edu
Status	Recruiting
Phase
Start date	October 5, 2020
Completion date	June 30, 2023

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT05916989` - Stimulant Use and Methylation in HIV
Recruiting	`NCT04927143` - Encouraging Abstinence Behavior in a Drug Epidemic	Phase 2
Completed	`NCT03226223` - Pharmacogenetics of Naltrexone for Stimulant Abuse	Phase 2
Not yet recruiting	`NCT05593796` - Cognitive Behavioral Therapy(CBT) in Treatment of Methamphetamine Use Disorder	N/A
Completed	`NCT02907853` - Contingency Management for Meth in South Africa Methamphetamine Abuse in South Africa	N/A
Completed	`NCT04061941` - Change in Cognitive Function in Stimulant Users
Completed	`NCT01967381` - Targeting GABA and Opioid Systems for a Pharmacotherapy for Methamphetamine Abuse	Early Phase 1
Terminated	`NCT01019707` - Safety Assessment of Atomoxetine With MA IV Administration	Phase 1
Completed	`NCT01011829` - Varenicline vs Placebo for the Treatment of Methamphetamine Dependence	Phase 2
Active, not recruiting	`NCT04706624` - Screen, Treat and Retain Meth-using People With Opioid Use Disorders at Methadone Clinics	N/A
Recruiting	`NCT05700994` - Peer Engagement in Methamphetamine Harm-Reduction With Contingency Management (PEER-CM)	N/A
Completed	`NCT04109014` - FASTLANE II: Reducing Sex, Drug, and Mental Health Risk	N/A
Completed	`NCT03336866` - Study of Antibody for Methamphetamine Outpatient Therapy	Phase 1/Phase 2
Completed	`NCT01822132` - Risky Decision Making in Methamphetamine Users: The Role of Opioid Blockade	N/A
Completed	`NCT01062451` - An ACE Inhibitor (Perindopril) or an Angiotensin Receptor Blocker (Candesartan) as a Treatment for Methamphetamine Dependence	Phase 1
Not yet recruiting	`NCT06233799` - Trial of Naltrexone/Bupropion for the Treatment of Methamphetamine Use Disorder	Phase 3
Recruiting	`NCT05521854` - Contingency Management for Drug Use: Does Age Matter?	N/A
Completed	`NCT01063205` - NAC as a Potential Treatment for Methamphetamine Dependence	Phase 1
Not yet recruiting	`NCT05334914` - ACT for Methamphetamine Use Disorder in Women and Gender Non-Conforming Individuals	N/A
Terminated	`NCT05034874` - Multiple-Dose Study to Evaluate the Safety and Efficacy of IXT-m200	Phase 2